Rhumbline Advisers Acquires Shares of 67,184 Immunome, Inc. (NASDAQ:IMNM)

Rhumbline Advisers acquired a new stake in Immunome, Inc. (NASDAQ:IMNM) during the second quarter, according to its most recent filing with the SEC. The firm acquired 67,184 shares of the company’s stock, valued at approximately $813,000. Rhumbline Advisers owned about 0.11% of Immunome as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. EntryPoint Capital LLC lifted its stake in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Immunome in the 2nd quarter valued at $97,000. Jump Financial LLC acquired a new position in shares of Immunome in the 4th quarter valued at $172,000. Sequoia Financial Advisors LLC acquired a new position in shares of Immunome in the 2nd quarter valued at $206,000. Finally, Sei Investments Co. acquired a new position in shares of Immunome in the 1st quarter valued at $469,000. 44.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Piper Sandler cut their price target on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $29.00.

Immunome Price Performance

IMNM opened at $14.00 on Tuesday. The business’s 50-day moving average price is $14.54 and its two-hundred day moving average price is $15.94. Immunome, Inc. has a 1 year low of $6.80 and a 1 year high of $30.96. The company has a market capitalization of $839.57 million, a price-to-earnings ratio of -1.85 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The firm had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. Sell-side analysts anticipate that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In other Immunome news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares in the company, valued at approximately $222,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the transaction, the chief financial officer now owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.